Madrigal Pharmaceuticals, Inc. Common Stock

**$MDGL** up big - Madrigal Stock Triples After Liver Disease Drug Succeeds in Trial
(Bloomberg) -- Madrigal Pharmaceuticals Inc. shares surged 268%, adding about $2.9 billion to its market value, after a late-stage clinical trial of its drug candidate met the main goals in patients with a type of liver disease.



Finally. A successful stage 3 NASH tx. 

obeticholic acid
Intercept Pharma’s drug. 
Genfits- Elafibranor in 2021
Bristol Meyers Squib - pegbelfermin
NGM Biopharmaceuticals drug
Horizon Therapuetics

ALL failed…

Background
Current leading cause of liver fibrosis is Hepatitis C (a chronic viral infection). But since Gilead and others effectively cured Hep C. The future leading cause of liver fibrosis will be NASH - non-alcoholic steatohepatitis. 

This is when excess fat is stored in the liver -> with time can cause liver scarring -> fibrosis-> cirrhosis and failure or cancer. 

![image](https://cdn.commonstock.com/d668decc7f8035ac39814b5854c66f57355105c56510513ac0b08e83e158c924-335x725.png)
Madrigal media release looks great on the surface. I’ll have to ready the actual study to be sure. 